==== Front BMC Cancer BMC Cancer BMC Cancer 1471-2407 BioMed Central London 11102 10.1186/s12885-023-11102-y Research Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study Shi Yunjing 12 Qiu Zeping 12 Yu Jing 3 Li Zhuojin 12 Hua Sha 4 Chen Yanjia 1 Chen Xiaosong 3 Shen Kunwei 3 Jin Wei jinwei@shsmu.edu.cn 124 1 grid.412277.5 0000 0004 1760 6738 Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025 P. R. China 2 grid.16821.3c 0000 0004 0368 8293 Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025 P. R. China 3 grid.412277.5 0000 0004 1760 6738 Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 P.R. China 4 grid.16821.3c 0000 0004 0368 8293 Heart Failure Center, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, 149 S. Chongqing Road, Shanghai, 200020 P. R. China 3 7 2023 3 7 2023 2023 23 61516 12 2022 22 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background Insulin resistance is an overlapping risk factor for both heart and breast cancer, while its interaction with cardiotoxicity in breast cancer (BC) patients is not clear. This study investigated the impact of insulin resistance on cardiac remodeling in patients with human epidermal growth factor receptor 2 (HER2)-positive BC during and after trastuzumab therapy in real-world clinical practice. Methods HER2-positive BC patients who received trastuzumab treatment between December 2012 and December 2017 were reviewed and 441 patients with baseline metabolic indices and serial echocardiographic measurements (baseline, 6, 12, and 18 months) after trastuzumab therapy initiation were included. Repeated measurement analysis of variance was used to evaluate temporal trends in multiparameter echocardiography. Linear mixed model was applied to further evaluate the role of insulin resistance in forementioned changes. Correlation of homeostasis model assessment-estimated insulin resistance (HOMA-IR) and triglyceride-glucose index (TyG) levels to changes in echocardiography parameters was explored. Results Of 441 patients (mean age 54 ± 10 [SD] years), 61.8% received anthracycline-based chemotherapy, 33.5% received left-sided radiotherapy, 46% received endocrine therapy. No symptomatic cardiac dysfunction was observed over the therapy course. A total of 19 (4.3%) participants experienced asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), and the peak onset time was 12 months after the initiation of trastuzumab. Albeit relatively low CTRCD incidence, cardiac geometry remodeling, especially left atrial (LA) dilation over therapy was notable and was more severe in high HOMA-IR and TyG level groups (P < 0.01). Noteworthy, a partial reversibility of cardiac remodeling was observed with treatment cessation. Additionally, HOMA-IR level positively correlated to changes in LA diameter from baseline to 12 months (r = 0.178, P = 0.003). No significant association (all P > 0.10) was detected between HOMA-IR or TyG level and dynamic left ventricular parameter evaluation. Multivariate linear regression analysis demonstrated that higher HOMA-IR level was an independent determinant for LA enlargement in BC patients during anti-HER2 targeted therapy course after adjusting for confounding risk factors (P = 0.006). Conclusion Insulin resistance was associated with left atrial adverse remodeling (LAAR) in HER2-positive BC patients that received standard trastuzumab therapy, indicating that insulin resistance could be a supplementation to baseline cardiovascular risk stratification proforma for HER2-targeted antitumor therapies. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-023-11102-y. Keywords Breast cancer Insulin resistance Asymptomatic cancer therapy-related cardiac dysfunction Left atrial adverse remodeling http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 81970337 Program of Shanghai Academic/Technology Research Leader21XD1402100 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcClinical perspective What is New? HFA-ICOS elaborated several risk factors for HER2-targeted cancer therapies, while scarce studies explored novel biomarker for subclinical cardiotoxicity in cardio-oncology. We presented a real-world study where insulin resistance, an overlapping risk factor of cardiac remodeling and breast cancer mortality, was associated with left atrial dilation in HER2-positive breast cancer patients receiving standard trastuzumab therapy. What are the clinical implications? We first demonstrated the causal relation between the prediabetic state and cardiac remodeling in HER2-positive breast cancer patients and supposed insulin resistance as a novel risk factor for subclinical cardiotoxicity of trastuzumab treatment. This article provided novel insights into the crosstalk between metabolism, oncology and cardiology, setting the way forward for the cardio-oncology towards multidisciplinary cooperation. Introduction Breast cancer (BC) is the most common malignancy in women all over the world, among which human epidermal growth factor receptor 2-positive (HER2+) BC accounts for 20-30% patients [1]. Advancement in HER2-targeted agents, especially the first monoclonal antibody trastuzumab has shifted HER2-positive BC from an aggressive disease to one with a relatively favorable outlook [2]. Nonetheless, this treatment benefit comes with inevitable cardiac sequelae, which mainly exhibits as left ventricular ejection fraction (LVEF) decline, or even congestive heart failure [3–5]. With the survival prolongation, cardiovascular disease (CVD) was reported to be the prevalent cause of non-relapse-related mortality in HER2-positive BC patients [6, 7]. The Heart Failure Association (HFA) of the European Society of Cardiology together with the International Cardio-Oncology Society (ICOS) proposed charts for baseline cardiovascular (CV) risk stratification of several anticancer therapies [8]. According to the HFA-ICOS score, risk factors for anti-HER2 therapies include older age, pre-existing CVD, previous or concurrent anthracycline use, prior radiotherapy to left chest or mediastinum, obesity, hypertension and diabetes mellitus (DM)[9]. Among these risk factors, centripetal obesity, hypertension, hyperglycemia, hyperinsulinemia are all associated with metabolic syndrome (MeS)[10], which could predispose individuals to both CVD and cancer [7, 11, 12]. Insulin resistance (IR), defined as the uncoordinated glucose-lowering response for target tissues at a normal plasma insulin level, plays a key role in the etiology and pathogenesis of MeS [13, 14]. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) and triglyceride-glucose index (TyG) are two well recognized indictors of insulin resistance [15, 16]. The detrimental effect of IR on CVD and cancer has been illustrated. Mounting evidence revealed that IR mediated the development of atherosclerosis, myocardial infarction and heart failure (HF) to some extent [15, 17, 18]. For instance, a study from the University of Oxford which enrolled 4,344 UKPDS participants discovered that a doubled HOMA2-IR value in newly diagnosed T2DM patients was associated with a 5% greater risk of HF death and a 14% greater risk of HF onset over a median follow-up of 16.4 years [17]. Apart from overt HF, the predictive value of IR for subclinical cardiac adverse remodeling has also been proposed [19–21]. A prospective study evaluated multilayer global longitudinal strain (MGLS) of matched patients with or without IR and concluded that patients with higher HOMA-IR values had significantly lower strain values [22]. In terms of oncology, IR was reported to be associated with higher BC incidence and all-cause mortality [23–25]. In prior studies, severer IR was associated with 34% higher BC incidence and 78% higher all-cause mortality after a median of 19.8 years follow-up of 1328 postmenopausal women [24]. Interestingly, a recent study found that breast cancer would in turn induce insulin resistance via cancer-cell-secreted extracellular vesicles [26]. Additionally, IR played a role in the racial disparities in BC prognosis. Compared to white women, black women with more invasive BC tended to have higher HOMA-IR levels, and IR partly mediated the association between race and worse prognosis [25, 27]. As a hazard for both heart and breast cancer, the impact of IR on cardiotoxicity in HER2-positive BC patients has not been fully explored. Here, we investigated the association between insulin resistance and cardiac remodeling in HER2-positive BC survivors with serial echocardiography measurements during and after trastuzumab therapy in real-world clinical practice. Materials and methods Study population BC patients who received surgery at General Surgery Department, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine between December 2012 and December 2017 were retrospectively reviewed. A total of 1133 patients were HER2-positive and received adjuvant trastuzumab therapy (TT). All participants were East Asian. Trastuzumab was intravenously administered with an initial dose of 8 mg/kg followed by a maintenance dose of 6 mg/kg every 3 weeks for 12 months. The main exclusion criteria included: (1) hereditary breast cancer, (2) less than 1 year of TT course, (3) previous exposure to trastuzumab or other anti-HER2 agents, (4) history of other malignancy, (5) absence of baseline metabolic indices or serial echocardiography measurements (baseline, 6, 12, and 18 months). Eventually, 441 participants were enrolled for final analysis (Fig. 1). Asymptomatic cancer therapy-related cardiac dysfunction (CTRCD) was defined as a decrease in LVEF by ≥ 10% below 50% or ≥ 15% from baseline. This study was reviewed and approved by the independent Ethical Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and written informed consent was obtained from all participants. Fig. 1 Flow chart of patient enrollment Clinical, pathological and biochemical assessments Baseline characteristics including demographics, comorbidities, menstrual state, tumor staging, planned surgery, chemotherapy, radiotherapy, endocrine therapy, metabolic indices were retrieved from Shanghai Jiaotong University Breast Cancer Database (SJTUBCDB). The adjuvant therapy scheme for each patient was decided by a multidisciplinary team consisting of breast surgeons, medical oncologists, radiation oncologists, pathologists and specialized breast nurses. Histopathological evaluation of tumor histological subtype, grade and lymphovascular invasion was conducted by professional pathologists at the Department of Pathology of Ruijin Hospital in accordance with the World Health Organization classification [28]. Estrogen receptor positive (ER+) and progesterone receptor positive (PR+) tumors were defined as tumors with nuclear staining in ≥ 1% of tumor cells. Ki‑67 index was characterized as the proportion of nuclear-stain positive cells to the total number of cells in ≥ 1,000 invasive tumor cells. HER2 positivity was defined as immunohistochemistry score of 3 or fluorescence in situ hybridization positive. The blood samples were collected in a quiet, air-conditioned room after overnight fasting and after at least 20 min supine rest. Metabolic indices including fasting plasma glucose (FPG), insulin (FINS), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol (HDLC), triglycerides (TG) were assessed (HITACHI 912 Analyzer, Roche Diagnostics, Germany). HOMA-IR was calculated according to the formula: HOMA-IR = FINS (µU/L) × FPG (mmol/L) / 22.5. TyG was calculated using the formula: TyG = LN [TG (mg/dl) × FPG (mg/dl)] / 2. Body mass index (BMI) was calculated using the formula of weight/height2 (kilograms per square meter). Body surface area (BSA) was calculated using the formula: BSA = 0.0061 × height + 0.0128 × weight − 0.1529. Echocardiography examinations Transthoracic echocardiography was performed before and 6, 12, 18 months after the initiation of TT, via a commercially available system (Vivid-I; GE Healthcare, Milwaukee, WI) with a 1.9-3.8-MHz phased-array transducer. Two dimensional (2D), pulsed-Doppler imaging was performed from standard parasternal and apical transducer positions with 2D frame rates of 60 to 100 frames/s. All data were stored digitally, and offline data analysis was performed (EchoPac, version 7; GE Healthcare) at the termination of the study by two cardiologists blinded to the study members. Left ventricular dimensions and wall thickness including left ventricular end-systolic diameter (LVESD), end-diastolic diameter (LVEDD), interventricular septal wall thickness (IVST) and LV posterior wall thickness (LVPWT), in diastole (d), were made in the parasternal long axis with the M-mode cursor positioned just beyond the mitral leaflet tips, perpendicular to the long axis of the ventricle. Maximal left atrial diameter (LAD) was also observed in the parasternal long axis. Left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) were measured from the apical four chamber view and calculated by Simpson’s biplane method. The LVEF was determined as the difference between LVEDV and LVESV, relative to the LVEDV. All parameters were measured twice, and the average value was recorded. Relative wall thickness (RWT) was determined by the formula: RWT = (IVST + LVPWT) / LVEDD. LV mass was estimated by the formula: LV mass = 0.8 × 1.04 × (LVEDD + IVST + LVPWT)3 - LVEDD3 + 0.6. LVEDV, LVESV and LV mass were indexed by BSA calculated at each study time point. Statistical analysis Continuous variables were expressed as the mean and standard deviation (SD) if data were normally distributed or the median with interquartile ranges (IQR) if not. Normal distribution was evaluated with Kolmogorov-Smirnov test. Between-group differences (3 groups) were compared by one-way analysis of variance (ANOVA) if data were normally distributed or Kruskal-Wallis test if not, followed by post hoc Bonferroni test. Categorical data were summarized as proportions and frequencies and analyzed by Chi-square or Fisher’s exact test. Repeated measurement analysis of variance was used to evaluate temporal trends in multiparameter echocardiography. Linear mixed model was conducted to evaluate the impact of IR in forementioned changes. Correlation between IR and changes in echocardiography parameters was determined by Spearman’s correlation test. HOMA-IR was defined as a log-transformed continuous variable in linear regression model analysis and an ordinal variable divided by its tertiles with the lowest tertile as reference to evaluate its value. Multivariable linear regression analysis was implemented to interrogate the independent diagnostic value of HOMA-IR for LAAR. Coefficients were presented after adjusting for age, BMI, hypertension, previous CVD and whether or not receiving anthracycline-based chemotherapy, left-sided radiotherapy, endocrine therapy. All statistical analyses were performed with the SPSS 25.0 for Windows (SPSS, Inc., Chicago, IL, USA). A 2-tailed P < 0.05 was considered statistically significant. All authors had full access to the data in the study and took responsibility for the integrity of data and accuracy of data analysis. Results Basic characteristics of the studied population A total of 441 HER2-positive BC patients who received adjuvant TT for 1 year were enrolled in this study. Among them, 61.8% received anthracycline-based chemotherapy, 33.5% received left-sided radiotherapy, 46% received endocrine therapy. The proportion of diabetes and dyslipidemia were 7.7% and 1.8% respectively, while the level of HOMA-IR (1.79 [1.22–2.69]) and TyG (4.57 [4.42–4.75]) was higher than the normal range according to previous reports [29, 30]. The level of HOMA-IR was well correlated with TyG in this study (r = 0.560, P < 0.001) (Fig. 2). We then classified the study population into low, medium and high HOMA-IR tertiles, which ranged from 0.31 to 1.40, 1.41–2.35 and 2.36–9.51 respectively. It turned out that subjects with higher HOMA-IR level tended to have higher BMI, systolic blood pressure, fasting glucose index, fasting lipid index and more cardiometabolic complications. No between-group differences were present in terms of oncological features and anti-tumor formula (Table 1). As for baseline echocardiographic parameters, no significant differences in LVEF, LV volume, and LV mass were observed between three groups. Nonetheless, as IR had been reported to exert subclinical impact on concentric hypertrophy and left atrial remodeling, ahead of overt cardiac dysfunction, subjects with higher HOMA-IR level had increased LA diameters and thicker wall thickness at baseline (Table S1)[31]. Table 1 Baseline characteristics HOMA-IR tertiles low medium high P - value n 147 147 147 Range 0.31–1.40 1.41–2.35 2.36–9.51 Demographic characteristics Age, median (IQR) 54(13) 53(16) 57(12) 0.013 BMI, kg/m2, mean (SD) 21.43(3.56) 22.68(3.02) 24.34(3.83) < 0.001 SBP, mmHg, median (IQR) 122(20) 125(25) 134(27) < 0.001 DBP, mmHg, median (IQR) 73(13) 74(11) 74(14) 0.713 Menopause, n (%) 85(57.5%) 80(54.4%) 91(61.9%) 0.429 Comorbidity, n (%) Hypertension 17(11.6%) 18(12.2%) 46(31.3%) < 0.001 Diabetes mellitus 8(5.4%) 7(4.8%) 19(12.9%) 0.014 Hyperlipidemia 2(1.4%) 1(0.7%) 5(3.4%) 0.191 Cardiovascular diseasea 4(2.7%) 5(3.4%) 16(10.9%) 0.004 Renal dysfunctionb 2(1.4%) 1(0.7%) 1(0.7%) 0.777 Oncological features, n (%) TNM stage I-II 107(72.8%) 101(68.7%) 106(72.1%) 0.455 TNM stage III 25(17.0%) 36(24.5%) 32(21.8%) Mastectomy 114(77.4%) 108(73.5%) 120(82.9%) 0.416 Breast conserving surgery 28(19.3%) 30(20.4%) 23(15.6%) Histology type: IDC 78(53.1%) 86(58.5%) 87(59.2%) 0.655 ER or PR+ 66(48.9%) 67(47.2%) 60(42.6%) 0.548 Ki67 ≥ 14 122(83.0%) 126 (85.7%) 127(86.4%) 0.688 Anthracycline-based chemotherapy 90(60.8%) 93(62.4%) 91(61.8%) 0.169 Left-sided radiotherapy 49(33.1%) 54(36.2%) 45(31.0%) 0.635 Endocrine therapy 67(45.6%) 72(49.0%) 66(44.9%) 0.476 Laboratory values, mean (SD) Fasting glucose, mmol/L 4.90(0.52) 5.09(0.62) 5.65(1.32) < 0.001 Fasting insulin, µU/mL 4.80(1.71) 7.73(1.49) 12.58(4.99) < 0.001 Triglyceride, mmol/L 0.91(0.52) 1.15(0.62) 1.43(0.82) < 0.001 Total cholesterol, mmol/L 4.75(1.39) 5.03(1.14) 4.89(1.37) 0.049 HDL cholesterol, mmol/L 1.50(0.45) 1.40(0.43) 1.26(0.36) < 0.001 LDL cholesterol, mmol/L 2.81(1.18) 3.08(1.00) 3.04(0.96) 0.169 aCardiovascular disease referred to arrhythmia, coronary heart disease and myositis bRenal dysfunction is defined as glomerular filtration rate (eGFR) < 60 ml /min/1.73m2 BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, IDC invasive ductal carcinoma, ER estrogen receptor positive, PR progesterone receptor positive, HDL high-density lipoprotein, LDL low-density lipoprotein, IQR interquartile range, SD standard deviation. Fig. 2 Spearman’s correlation between HOMA-IR and TyG. HOMA-IR homeostasis model assessment-estimated insulin resistance, TyG triglyceride-glucose index Dynamic changes in echocardiographic geometric and functional properties over adjuvant trastuzumab therapy Transthoracic echocardiography examinations before and 6,12,18 months after the initiation of 1-year course of TT were conducted according to the position statement [32]. At baseline, no one was concomitant with HF or LV systolic dysfunction. Over the therapy course, 5 patients experienced a decline of LVEF ＞15% but still within the normal range at 6 months. The number added up to 16 at 12 months, and 4 of whom had a drop of LVEF below 50%. However, half of the patients partly recovered from CTRCD after the TT termination and only 2 patients retained the LVEF under 50%. Interestingly, the baseline HOMA-IR levels of aforementioned patients suffering from CTRCD were found to be significantly higher than those event-free patients, whenever the event occurred (Table S2). Repeated measurement analysis of variance was used to evaluate longitudinal multiparameter changes of echocardiography over the course of TT. Albeit relatively low CTRCD incidence, there was a deterioration of cardiac geometry structure and function manifested as LA enlargement (P = 0.014), LV dilation (LVESV, LVEDV, both P < 0.001) and LVEF decline (P = 0.080) from baseline to 12 months, while the situation was partly reversed 6 months after the cessation of TT (Fig. 3). Additionally, when grouped by HOMA-IR tertiles, only the temporal changes of LA parameter were significantly different between groups, indicating that IR degree exerted impact on LA remodeling in BC patients over the TT (Pint = 0.007, Fig. 4). Fig. 3 Temporal trends in echocardiography indices before, during and after trastuzumab therapy. LAD left atrial diameter, LVESV left ventricular end-systolic volume, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction. P values in the graph titles refer to overall comparisons across 4 time points via repeated measurement analysis of variance. Vertical bars indicate 95% confidence interval (CI). Fig. 4 Temporal trends in LAD before, during and after trastuzumab therapy among HOMA-IR tertiles. HOMA-IR homeostasis model assessment-estimated insulin resistance, LAD left atrial diameter To further assess the impact of IR on cardiac remodeling, follow-up echocardiography parameters were compared in subjects stratified by HOMA-IR and TyG levels (Table 2, S3). No significant differences were discovered between groups in terms of LVEF that tended to be the main metric of CTRCD, so as other LV parameters. Nonetheless, we found LA diameter increased with increasing tertiles of HOMA-IR and TyG at follow-up time points, which raised our interest. Hence, changes of LA diameters from baseline between different levels of HOMA-IR and TyG tertiles were explored. Interestingly, there was an upward inclination in LA dilation at 12 months and 18 months compared to baseline with increasing tertiles of HOMA-IR (ΔLAD12m, P < 0.05). Likewise, a similar trend was observed between different groups of TyG at 12 months (Fig. 5). Above all, we preliminary supposed that LA dilation over therapy was significant and was more severe in high IR level groups. Table 2 Follow-up echocardiography parameters grouped by HOMA-IR tertiles over the trastuzumab therapy course Tertiles HOMAIR low HOMA-IR medium HOMA-IR high P - value LAD 0 33.75(3.54) 34.39(3.27) 35.28(3.58) 0.003 6 m 34.32(3.31) 35.46(3.41) 35.69(3.30) 0.035 12 m 34.31(3.56) 35.32(3.15) 35.98(3.38) 0.002 18 m 34.26(3.62) 34.85(3.18) 36.15(3.08) < 0.001 LVEF 0 68.15(3.71) 67.91(3.84) 68.25(3.88) 0.787 6 m 66.29(4.45) 66.75(3.85) 67.10(3.94) 0.504 12 m 66.00(4.84) 66.07(4.25) 65.63(5.42) 0.780 18 m 65.87(4.22) 65.98(3.85) 66.33(4.54) 0.716 LVMi 0 74.90(13.70) 76.53(12.11) 77.21(13.49) 0.396 6 m 78.39(14.29) 79.46(13.03) 78.65(12.42) 0.887 12 m 78.80(10.77) 79.81(12.80) 80.66(12.44) 0.545 18 m 77.58(13.55) 77.07(11.84) 79.24(13.34) 0.457 RWT 0 0.371(0.034) 0.370(0.036) 0.392(0.047) < 0.001 6 m 0.368(0.039) 0.373(0.040) 0.380(0.042) 0.231 12 m 0.362(0.031) 0.368(0.035) 0.376(0.038) 0.016 18 m 0.362(0.035) 0.368(0.037) 0.374(0.038) 0.070 Values are given as mean (SD) HOMA-IR homeostasis model assessment-estimated insulin resistance, LAD left atrial diameter, LVEF left ventricular ejection fraction, LVMi left ventricular mass indexed to body surface area, RWT relative wall thickness. Fig. 5 Distribution of changes in LAD at 12 months and 18months after the trastuzumab therapy compared to baseline among HOMA-IR (a) and TyG (b) tertiles. HOMA-IR homeostasis model assessment-estimated insulin resistance, TyG triglyceride-glucose index, LAD left atrial diameter, Data are expressed as mean ± 95% confidence interval. One-way ANOVA with Bonferroni multiple comparisons test was used. *P < 0.05 The association between insulin resistance and LA dilation in breast cancer patients during anti-HER2 targeted therapy course As HER2-positive BC patients experienced the severest cardiac remodeling at 12 months after the initiation of TT, correlation between HOMA-IR and echocardiographic parameters changes at 12 months was further investigated. And it turned out that Log-transformed HOMA-IR level positively correlated to changes in LA diameter from baseline to 12 months (r = 0.178, P = 0.003) (Fig. 6). No significant association (all P > 0.10) was detected between HOMA-IR or TyG level and dynamic LV diameter and volume parameter evaluation (Table S4). Fig. 6 Spearman’s correlation between Log-transformed HOMA-IR and changes in LA dimension from baseline to 12 months. HOMA-IR homeostasis model assessment-estimated insulin resistance, LAD left atrial diameter Finally, multivariate linear regression was performed to interrogate the association between IR and LA dilation (Table 3). In model 1, after adjusting for confounding clinical variables including age, BMI, hypertension and prior cardiovascular disease, HOMA-IR (as a log-transformed continuous variable) was independently associated with changes in ΔLAD12m [β (95%CI): 2.19 (0.64–3.75), P = 0.006]. Compared with the low tertile, high tertiles of HOMA-IR corresponded to 0.87-mm and 1.13-mm increases in LAD. In model 2, we further included whether or not receiving anthracycline-based chemotherapy, left-sided radiotherapy, endocrine therapy to rule out the impact of different treatment regimens [β (95%CI): 1.69 (0.13–3.25), P = 0.034]. In summary, higher HOMA-IR level was an independent determinant for LA enlargement. In a word, insulin resistance played a role in suboptimal cardiovascular health in BC patients during TT course. Table 3 Multivariable linear regression models for HOMA-IR as a risk factor for LA remodeling Model 1 Model 2 Variables Coefficient (95% CI) Sβ P – value Coefficient (95% CI) Sβ P - value lg HOMA-IR per SD 2.19(0.64–3.75) 0.196 0.006 1.69(0.13–3.25) 0.151 0.034 First tertile 1 (Reference) … 1 (Reference) … Second tertile 0.87(-0.06-1.80) 0.140 0.065 0.81(-0.11-1.74) 0.130 0.086 Third tertile 1.13(0.19–2.07) 0.190 0.019 0.95(0.00-1.90) 0.159 0.050 Model 1, adjusted for age, body mass index, hypertension, cardiovascular disease Model 2, adjusted for age, body mass index, whether or not receiving anthracycline-based chemotherapy, left-sided radiotherapy, endocrine therapy HOMA-IR homeostatic model assessment-insulin resistance, CI confidence interval, SD standard deviation Discussion The major finding of the current study was that relatively low CTRCD incidence but significant cardiac remodeling, especially LA enlargement, existed in HER2-positive BC patients receiving standard anti-tumor therapy. And insulin resistance was an independent determinant for LA enlargement that reflected subclinical cardiotoxicity. Monitoring of cardiac function is of critical importance for CTRCD surveillance and prevention in BC patients. Echocardiography is recommended as the first-line modality for the assessment of cardiac function in patients with cancer [33]. Serial measurement of LVEF is the most widely applied approach, while it is insensitive for detecting early cardiac dysfunction in case of contractility reserve. As the early detection and prompt intervention of minor cardiac damage are increasingly emphasized in recent years, cardio-oncology appeals for more sensitive indicators that assess diastolic function or myocardial lesions [5, 34]. Among these evaluation metrics, LAAR has been widely reported to be an early sign of asymptomatic cardiac dysfunction despite preserved systolic and diastolic function [35, 36]. In a recent large-scale community-based study which enrolled 2221 healthy participants, multiple echocardiographic parameters of LA were found to be related to HF development after a median follow-up of 15.8 years. Among which the minimum LA volumes indexed to BSA (LAVimin) was the strongest predictor of incident HF [37]. In our study in the non-clinical trial setting, the rate of asymptomatic CTRCD was low probably due to overall low HFA-ICOS baseline CV risk scores. Nonetheless, LAAR trend observed over TT course should not be overlooked for that it might be the herald of late cardiac complications. In line with our study, Flora et al. observed that HER2-positive BC patients suffered from significant decline in LA ejection fraction and increase in LA minimum volume during and after TT via a small prospective 2-center longitudinal study [34]. Lisi et al. discovered that alteration of LA strain (LAS) and LA stiffness index (LASI) preceded that of LV parameters, LV global longitudinal strain (GLS) included, in identifying asymptomatic TT related cardiac dysfunction [38]. Moreover, since trastuzumab-induced cardiotoxicity was considered to be reversible, TT related LAAR was also partly reversed 6 months after the cessation of the course in our cohort. HFA-ICOS had elaborated several risk factors for HER2-targeted cancer therapies, while scarce studies explored novel biomarkers for subclinical cardiotoxicity in cardio-oncology. IR was reported to be associated with adverse cardiac remodeling and poor prognosis of BC as well. As reported by prior studies, higher level of HOMA-IR was accompanied by lower LAS and higher LASI in general population [39, 40]. IR also increased the susceptibility to incident atrial fibrillation (AF) and AF recurrence after ablation partly due to the atrial electrical remodeling [41, 42]. In this study, we first found that higher IR degree was responsible for more significant LAAR but not LV structural and functional deterioration during and after TT. With increasing tertiles of HOMA-IR or TyG, an upward inclination in LA dilation persisted till 6 months after therapy cessation though the changes of LA diameters from baseline between different levels of HOMA-IR was only statistically significant at 12 months (ΔLAD12m, P < 0.05). After adjusting for confounding clinical variables, including well-recognized risk factors for HER2-targeted cancer therapies proposed by HFA-ICOS, IR was independently associated with LA enlargement in HER2-positive BC patients. Furthermore, 61.8% received anthracycline-based chemotherapy and 33.6% underwent left-sided radiotherapy in our cohort. Anthracycline application moderately modified the association of HOMA-IR with changes in LAD at 12months, suggesting that the combination of anthracycline and trastuzumab exacerbated the risk of LAAR as well. Nonetheless, forementioned effect was not present in patients coincided with left-sided radiotherapy. The underline mechanism may be the sophisticated interaction between IR, myocardial dysfunction, BC biology and HER2 signaling. First, IR related with numerous adverse effects in the heart including perturbation in myocardial energy metabolism, mitochondrial dysfunction, endoplasmic reticulum stress, calcium homeostasis imbalance and immune response incoordination. These pathological changes fired the susceptibility of myocardial damage in that HER2 inhibition also increased ROS production, induced mitochondrial function deterioration and diminished cardioprotective effects of neuregulin 1[43]. Secondly, insulin receptor, insulin-like growth factor 1 receptor ( IGF-1R) and HER2 all belong to the tyrosine kinase receptor superfamily, insulin could directly or indirectly activated the IR/IGF-1R/HER2 signaling pathway [44, 45], promoting the growth and metastasis of BC cells, contributing to trastuzumab resistance and trastuzumab-induced cardiotoxicity in HER2-positive BC patients [46, 47]. Thirdly, systemic IR may contribute to myocardial IR, pushing forward the cardiac remodeling in early stage [48]. Myocardial insulin signaling includes two key pathways. The first pathway involving insulin receptor substrate 1/ phosphatidylinositol 3-kinase (IRS-1/PIK3) predominantly elicits metabolic responses, while the second pathway via mitogen-activated protein kinase (MAPK) mainly exerts growth promoting effects, contributing to the resultant myocardial hypertrophy and cardiac fibrosis [49]. IR status could reflect an imbalance between the metabolic and growth pathways of insulin signaling in the myocardium, with the actions of the MAPK predominating over the increased phosphorylated IRS-1/PI3K pathway [50]. Herein, IR exerted a complicated and profound impact on myocardial function in BC patients receiving anti-HER2 therapy. The primary prevention of CV toxicity emphasizes lifestyle optimization and early intervention of CV risk factors, namely giving propriety to cardiometabolic health management. In our study, we first demonstrated the causative relation between this prediabetic state and cardiac remodeling in HER2-positive BC patients and supposed IR as another novel risk factor for asymptomatic CTRCD. Moreover, we provided a novel insight into the crosstalk between metabolism, oncology and cardiology, setting the way forward for the cardio-oncology towards multidisciplinary cooperation. Study limitations We appreciate limitations in our study. First, this was a retrospective study based on prospectively collected data. Second, the evaluation of LA and LV remodeling was limited to echocardiography parameters. Cardiac magnetic resonance would provide more information. Further prospective studies are warranted to comprehensively assess the impact of IR on the composite endpoint integrating cardiology and oncology. Conclusions In conclusion, this study revealed that insulin resistance was associated with LA dilation in HER2-positive BC patients receiving 1-year of TT in real-world clinical practice, which could be recognized as a sensitive indicator for asymptomatic CTRCD. We appeal for the cardiometabolic health management in BC patients since appropriate intervention of IR would promote a win-win outcome for both heart and breast cancer. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations HER2 human epidermal growth factor receptor 2 HOMA-IR homeostasis model assessment-estimated insulin resistance TyG triglyceride-glucose index CTRCD cancer therapy-related cardiac dysfunction LAAR left atrial adverse remodeling BC breast cancer HFA Heart Failure Association ICOS International Cardio-Oncology Society MeS metabolic syndrome IR insulin resistance MGLS multilayer global longitudinal strain LAS LA strain LASI LA stiffness index GLS global longitudinal strain IGF-1R insulin-like growth factor 1 receptor IRS-1/PIK3 insulin receptor substrate 1/ phosphatidylinositol 3-kinase MAPK mitogen-activated protein kinase Acknowledgements None. Author contributions WJ and ZQ proposed the study design. YS performed data analysis, data interpretation, and manuscript writing. JY, ZL, SH, YC performed data collection. XC, KS and WJ performed manuscript revision. All authors reviewed the manuscript. Funding This work was supported by grants from the National Natural Science Foundation of China (81970337 and 82270404) and Program of Shanghai Academic/Technology Research Leader (21XD1402100). Data Availability All data generated or analyzed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate This study was reviewed and approved by the independent Ethical Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and written informed consent was obtained from all participants. Tissue samples and patient data used in this study were provided by the independent Ethical Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. This study was performed in accordance with the Declaration of Helsinki. All experiments were performed in accordance with relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare that they have no conflicts of interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yunjing Shi and Zeping Qiu contributed equally to this work and should be considered co-first authors. ==== Refs References 1. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001 344 11 783 92 10.1056/NEJM200103153441101 11248153 2. Jerusalem G Lancellotti P Kim SB HER2 + breast cancer treatment and cardiotoxicity: monitoring and management Breast Cancer Res Treat 2019 177 2 237 50 10.1007/s10549-019-05303-y 31165940 3. de Azambuja E Procter MJ van Veldhuisen DJ Agbor-Tarh D Metzger-Filho O Steinseifer J Untch M Smith IE Gianni L Baselga J Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01) J Clin Oncol 2014 32 20 2159 65 10.1200/JCO.2013.53.9288 24912899 4. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2021. 5. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the european Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022. 6. Dempsey N Rosenthal A Dabas N Kropotova Y Lippman M Bishopric NH Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies Breast Cancer Res Treat 2021 188 1 21 36 10.1007/s10549-021-06280-x 34115243 7. Karlstaedt A Barrett M Hu R Gammons ST Ky B Cardio-Oncology: understanding the Intersections between Cardiac Metabolism and Cancer Biology JACC Basic Transl Sci 2021 6 8 705 18 10.1016/j.jacbts.2021.05.008 34466757 8. Lyon AR Dent S Stanway S Earl H Brezden-Masley C Cohen-Solal A Tocchetti CG Moslehi JJ Groarke JD Bergler-Klein J Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the heart failure association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society Eur J Heart Fail 2020 22 11 1945 60 10.1002/ejhf.1920 32463967 9. Battisti NML Andres MS Lee KA Ramalingam S Nash T Mappouridou S Senthivel N Asavisanu K Obeid M Tripodaki ES Incidence of cardiotoxicity and validation of the heart failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer Breast Cancer Res Treat 2021 188 1 149 63 10.1007/s10549-021-06192-w 33818652 10. Dieli-Conwright CM Nelson RA Simon MS Irwin ML Neuhouser ML Reding KW Crane TE Manson JE Nassir R Shadyab AH Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the women’s Health Initiative BMC Womens Health 2022 22 1 32 10.1186/s12905-022-01614-3 35120497 11. Moslehi J Zhang Q Moore KJ Crosstalk between the Heart and Cancer: Beyond Drug Toxicity Circulation 2020 142 7 684 7 10.1161/CIRCULATIONAHA.120.048655 32804565 12. de Boer RA Hulot JS Tocchetti CG Aboumsallem JP Ameri P Anker SD Bauersachs J Bertero E Coats AJS Celutkiene J Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the heart failure Association (HFA) of the European Society of Cardiology (ESC) Eur J Heart Fail 2020 22 12 2272 89 10.1002/ejhf.2029 33094495 13. Simon MS Beebe-Dimmer JL Hastert TA Manson JE Cespedes Feliciano EM Neuhouser ML Ho GYF Freudenheim JL Strickler H Ruterbusch J Cardiometabolic risk factors and survival after breast cancer in the women’s Health Initiative Cancer 2018 124 8 1798 807 10.1002/cncr.31230 29338086 14. Petersen MC Shulman GI Mechanisms of insulin action and insulin resistance Physiol Rev 2018 98 4 2133 223 10.1152/physrev.00063.2017 30067154 15. Yang CD Shen Y Lu L Ding FH Yang ZK Zhang RY Shen WF Jin W Wang XQ Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients Cardiovasc Diabetol 2019 18 1 100 10.1186/s12933-019-0904-3 31391045 16. Miao M, Zhou G, Bao A, Sun Y, Du H, Song L, Cao Y, You S, Zhong C. Triglyceride-glucose index and common carotid artery intima-media thickness in patients with ischemic stroke. Cardiovasc Diabetol 2022, 21(1). 17. Wamil M Coleman RL Adler AI McMurray JJV Holman RR Increased risk of Incident Heart failure and death is Associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89 Diabetes Care 2021 44 8 1877 84 10.2337/dc21-0429 34162666 18. Vardeny O Gupta DK Claggett B Burke S Shah A Loehr L Rasmussen-Torvik L Selvin E Chang PP Aguilar D Insulin resistance and incident heart failure the ARIC study (atherosclerosis risk in Communities) JACC Heart Fail 2013 1 6 531 6 10.1016/j.jchf.2013.07.006 24455475 19. Ocaranza MP Bambs C Salinas M Matamala C Garcia L Troncoso R Pedrozo Z Huidobro A Venegas P Paredes F Early left atrial dysfunction is associated with suboptimal cardiovascular health Echocardiography 2020 37 1 47 54 10.1111/echo.14568 31851399 20. Shigematsu Y Norimatsu S Ogimoto A Ohtsuka T Okayama H Higaki J The influence of insulin resistance and obesity on left atrial size in japanese hypertensive patients Hypertens Res 2009 32 6 500 4 10.1038/hr.2009.41 19373236 21. Cook SA Varela-Carver A Mongillo M Kleinert C Khan MT Leccisotti L Strickland N Matsui T Das S Rosenzweig A Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction Eur Heart J 2010 31 1 100 11 10.1093/eurheartj/ehp396 19797329 22. Atici A Asoglu R Barman HA Sarikaya R Arman Y Tukek T Multilayer global longitudinal strain assessment of subclinical myocardial dysfunction related to insulin resistance Int J Cardiovasc Imaging 2021 37 2 539 46 10.1007/s10554-020-02037-7 32951097 23. Iwase T Sangai T Fujimoto H Sawabe Y Matsushita K Nagashima K Sato Y Nakagawa A Masuda T Nagashima T Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer Breast Cancer Res Treat 2020 179 2 435 43 10.1007/s10549-019-05467-7 31620935 24. Pan K Chlebowski RT Mortimer JE Gunter MJ Rohan T Vitolins MZ Adams-Campbell LL Ho GYF Cheng TD Nelson RA Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the women’s Health Initiative Cancer 2020 126 16 3638 47 10.1002/cncr.33002 32530506 25. Gallagher EJ Fei K Feldman SM Port E Friedman NB Boolbol SK Killelea B Pilewskie M Choi L King T Insulin resistance contributes to racial disparities in breast cancer prognosis in US women Breast Cancer Res 2020 22 1 40 10.1186/s13058-020-01281-y 32393319 26. Cao M Isaac R Yan W Ruan X Jiang L Wan Y Wang J Wang E Caron C Neben S Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth Nat Cell Biol 2022 24 6 954 67 10.1038/s41556-022-00919-7 35637408 27. Gordon NT Alberty-Oller JJ Fei K Greco G Gallagher EJ LeRoith D Feldman SM Killilea B Boolbol SK Choi L Association of insulin resistance and higher oncotype DX Recurrence score Ann Surg Oncol 2021 28 11 5941 7 10.1245/s10434-021-09748-8 33813671 28. Frank GA Danilova NV Andreeva I Nefedova NA [WHO classification of tumors of the breast, 2012] Arkh Patol 2013 75 2 53 63 24006766 29. Shah RV Abbasi SA Heydari B Rickers C Jacobs DR Jr Wang L Kwong RY Bluemke DA Lima JA Jerosch-Herold M Insulin resistance, subclinical left ventricular remodeling, and the obesity paradox: MESA (multi-ethnic study of atherosclerosis) J Am Coll Cardiol 2013 61 16 1698 706 10.1016/j.jacc.2013.01.053 23500236 30. Hedblad B Nilsson P Engström G Berglund G Janzon L Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death Diabet Med 2002 19 6 470 5 10.1046/j.1464-5491.2002.00719.x 12060058 31. Markus MRP Rospleszcz S Ittermann T Baumeister SE Schipf S Siewert-Markus U Lorbeer R Storz C Ptushkina V Peters A Glucose and insulin levels are associated with arterial stiffness and concentric remodeling of the heart Cardiovasc Diabetol 2019 18 1 145 10.1186/s12933-019-0948-4 31684945 32. Čelutkienė J Pudil R López-Fernández T Grapsa J Nihoyannopoulos P Bergler-Klein J Cohen-Solal A Farmakis D Tocchetti CG von Haehling S Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the heart failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) Eur J Heart Fail 2020 22 9 1504 24 10.1002/ejhf.1957 32621569 33. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the european Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022. 34. Huang F, Brezden-Masley C, Chan KKW, Barfett JJ, Kirpalani A, Deva DP, Jimenez-Juan L, Barthur A, Song L, Chacko B et al. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab. Eur Radiol 2022. 35. Triposkiadis F Pieske B Butler J Parissis J Giamouzis G Skoularigis J Brutsaert D Boudoulas H Global left atrial failure in heart failure Eur J Heart Fail 2016 18 11 1307 20 10.1002/ejhf.645 27813305 36. Bisbal F Baranchuk A Braunwald E Bayes de Luna A Bayes-Genis A Atrial failure as a clinical entity: JACC Review topic of the Week J Am Coll Cardiol 2020 75 2 222 32 10.1016/j.jacc.2019.11.013 31948652 37. Andersen DM Sengeløv M Olsen FJ Marott JL Jensen GB Schnohr P Platz E Schou M Mogelvang R Biering-Sørensen T Measures of left atrial function predict incident heart failure in a low-risk general population: the Copenhagen City Heart Study Eur J Heart Fail 2022 24 3 483 93 10.1002/ejhf.2406 34931395 38. Novo G Di Lisi D Manganaro R Manno G Lazzara S Immordino FA Madaudo C Carerj S Russo A Incorvaia L Arterial stiffness: Effects of Anticancer Drugs used for breast Cancer Women Front Physiol 2021 12 661464 10.3389/fphys.2021.661464 34054578 39. Mahfouz RA Gomma A Goda M Safwat M Relation of left atrial stiffness to insulin resistance in obese children: Doppler strain imaging study Echocardiography 2015 32 7 1157 63 10.1111/echo.12824 25363045 40. Marcovecchio ML Gravina M Gallina S D’Adamo E De Caterina R Chiarelli F Mohn A Renda G Increased left atrial size in obese children and its association with insulin resistance: a pilot study Eur J Pediatr 2016 175 1 121 30 10.1007/s00431-015-2608-3 26272254 41. Wang Z, Wang YJ, Liu ZY, Li Q, Kong YW, Chen YW, Sun YH, Dong JZ. Effect of insulin resistance on recurrence after Radiofrequency catheter ablation in patients with Atrial Fibrillation. Cardiovasc Drugs Ther 2022. 42. Polovina M Krljanac G Asanin M Seferovic PM Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation Eur J Prev Cardiol 2020 27 18 1931 3 10.1177/2047487320912626 32237896 43. Leemasawat K Phrommintikul A Chattipakorn SC Chattipakorn N Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients Cell Mol Life Sci 2020 77 8 1571 89 10.1007/s00018-019-03340-w 31650186 44. Memon AA Bennet L Zoller B Wang X Palmer K Sundquist K Sundquist J Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance J Diabetes 2015 7 3 369 77 10.1111/1753-0407.12184 24981162 45. Arcidiacono D Antonello A Fassan M Nucci D Morbin T Agostini M Nitti D Rugge M Alberti A Battaglia G Insulin promotes HER2 signaling activation during Barrett’s Esophagus carcinogenesis Dig Liver Dis 2017 49 6 630 8 10.1016/j.dld.2017.01.154 28185837 46. Luo L Zhang Z Qiu N Ling L Jia X Song Y Li H Li J Lyu H Liu H Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers herceptin resistance in HER2-positive breast cancer Nat Commun 2021 12 1 2699 10.1038/s41467-021-23052-9 33976188 47. Novosyadlyy R Lann DE Vijayakumar A Rowzee A Lazzarino DA Fierz Y Carboni JM Gottardis MM Pennisi PA Molinolo AA Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes Cancer Res 2010 70 2 741 51 10.1158/0008-5472.CAN-09-2141 20068149 48. Gargiulo P Perrone-Filardi P Heart failure, whole-body insulin resistance and myocardial insulin resistance: an intriguing puzzle J Nucl Cardiol 2018 25 1 177 80 10.1007/s12350-016-0586-0 27484212 49. Karwi QG Jörg AR Lopaschuk GD Allosteric, transcriptional and post-translational control of mitochondrial energy metabolism Biochem J 2019 476 12 1695 712 10.1042/BCJ20180617 31217327 50. Jia G DeMarco VG Sowers JR Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy Nat Rev Endocrinol 2016 12 3 144 53 10.1038/nrendo.2015.216 26678809